Pilot early phase II study of decitabine and carboplatin in patients with advanced melanoma

INTRODUCTION: Resistance to targeted and immune checkpoint blockade treatment remains a major problem in patients with advanced metastatic melanoma. To overcome this problem, there needs to be a decrease in burden of disease as well as re-establishing of immune sensitivity. The aim of this early pha...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Westhuizen, Andre, Knoblauch, Naomi, Graves, Moira C., Levy, Richard, Vilain, Ricardo E., Bowden, Nikola A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310888/
https://www.ncbi.nlm.nih.gov/pubmed/32569203
http://dx.doi.org/10.1097/MD.0000000000020705

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310888/
https://www.ncbi.nlm.nih.gov/pubmed/32569203
http://dx.doi.org/10.1097/MD.0000000000020705

Ejemplares similares